A recent study revealed that FGF21 treatment was associated with the better motor and cognitive performance of MPTP-induced mouse models of PD, possibly by re-structuring the profile of gut microbiota, thus preventing PD-related metabolic alterations in the gut [84]. This evidence concerns the gene FGF21 and Parkinson disease.